Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment
暂无分享,去创建一个
M. Loda | L. Liotta | S. Pennington | V. Espina | A. Fabre | R. Lis | Lisa Staunton | Michaela Bowden | S. Finn | C. Tonry | R. Inzitari | J. O'Leary | M. Bowden
[1] Lydie Lane,et al. Metrics for the Human Proteome Project 2016: Progress on Identifying and Characterizing the Human Proteome, Including Post-Translational Modifications. , 2016, Journal of proteome research.
[2] Jeffrey R. Whiteaker,et al. Commercially available antibodies can be applied in quantitative multiplexed peptide immunoaffinity enrichment targeted mass spectrometry assays , 2016, Proteomics.
[3] Jouhyun Jeon,et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer , 2016, Nature Communications.
[4] Yongheng Chen,et al. Proteomic analysis of stromal proteins in different stages of colorectal cancer establishes Tenascin-C as a stromal biomarker for colorectal cancer metastasis , 2016, Oncotarget.
[5] J. Foekens,et al. The advantage of laser‐capture microdissection over whole tissue analysis in proteomic profiling studies , 2016, Proteomics.
[6] Alexander L. Vahrmeijer,et al. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery , 2016, Molecular Imaging and Biology.
[7] A. Laurinavičienė,et al. Comprehensive Immunohistochemistry: Digital, Analytical and Integrated , 2016, Pathobiology.
[8] S. Carr,et al. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. , 2016, Journal of proteome research.
[9] L. Egevad,et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.
[10] M. Mason,et al. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes , 2016, Oncotarget.
[11] Jingxia Li,et al. p85α promotes nucleolin transcription and subsequently enhances EGFR mRNA stability and EGF-induced malignant cellular transformation , 2016, Oncotarget.
[12] K. Guru,et al. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer , 2016, The Prostate.
[13] Joe Y. Chang,et al. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs , 2016, Tumor Biology.
[14] M. Loda,et al. Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LCMSA technical report , 2015, EuPA open proteomics.
[15] S. Ramsey,et al. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. , 2015, The oncologist.
[16] Ana C. Gregório,et al. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. , 2015, Biomaterials.
[17] A. Giordano,et al. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model , 2015, Oncotarget.
[18] P. Kantoff,et al. The role of miRNAs in prostate cancer. , 2015, European urology.
[19] Sarah J. Kurley,et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.
[20] Francesca Salipur,et al. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation , 2015, Molecular oncology.
[21] Y. Guan,et al. Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study. , 2015, Journal of proteome research.
[22] L. Rassenti,et al. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B , 2015, Haematologica.
[23] P. Bouvet,et al. The roles of nucleolin subcellular localization in cancer. , 2015, Biochimie.
[24] M. Loda,et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer , 2015, Clinical Cancer Research.
[25] S. Carr,et al. Antibody-based capture of target peptides in multiple reaction monitoring experiments. , 2015, Methods in molecular biology.
[26] M. Wicha,et al. Breast cancer stem cells: current advances and clinical implications. , 2015, Methods in molecular biology.
[27] M. M. Vivanco. Mammary Stem Cells , 2015, Methods in Molecular Biology.
[28] Matthias Mann,et al. The Q Exactive HF, a Benchtop Mass Spectrometer with a Pre-filter, High-performance Quadrupole and an Ultra-high-field Orbitrap Analyzer* , 2014, Molecular & Cellular Proteomics.
[29] Kyungeun Kim,et al. AZGP-1 Immunohistochemical Marker in Prostate Cancer: Potential Predictive Marker of Biochemical Recurrence in Post Radical Prostatectomy Specimens , 2014, Applied immunohistochemistry & molecular morphology : AIMM.
[30] Zhaohai Wang,et al. Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy , 2014, Diagnostic Pathology.
[31] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[32] Maolin Yan,et al. Nucleolin identified by comparative mass‑spectra analysis is a potential marker for invasive progression of hepatocellular carcinoma. , 2014, Molecular medicine reports.
[33] M. Loda,et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error , 2014, British Journal of Cancer.
[34] David L Rimm,et al. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality , 2014, Proteome Science.
[35] S. Pennington,et al. Why have so few proteomic biomarkers “survived” validation? (Sample size and independent validation considerations) , 2014, Proteomics.
[36] G. Klein. Evolutionary aspects of cancer resistance. , 2014, Seminars in cancer biology.
[37] William S. Hancock,et al. Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes. , 2014, Journal of proteome research.
[38] Amos Bairoch,et al. Metrics for the Human Proteome Project 2013-2014 and strategies for finding missing proteins. , 2014, Journal of proteome research.
[39] Malte Buchholz,et al. MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large‐scale tissue microarrays , 2013, International journal of cancer.
[40] H. Tsuda,et al. Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer. , 2013, Journal of proteomics.
[41] A. Vlahou,et al. Zinc α2‐glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer , 2012, BJU international.
[42] Albert J R Heck,et al. High-sensitivity Orbitrap mass analysis of intact macromolecular assemblies , 2012, Nature Methods.
[43] L. Kavoussi,et al. Clinical evaluation of a novel bipolar radiofrequency ablation system for renal masses , 2012, BJU international.
[44] R. Weil,et al. Targeted tissue proteomic analysis of human astrocytomas. , 2012, Journal of proteome research.
[45] A. Bergh,et al. The Stroma—A Key Regulator in Prostate Function and Malignancy , 2012, Cancers.
[46] D. Piwnica-Worms,et al. Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest , 2012, Journal of Neuro-Oncology.
[47] B. Engels,et al. Targeting stroma to treat cancers. , 2012, Seminars in cancer biology.
[48] D R Mani,et al. Interlaboratory Evaluation of Automated, Multiplexed Peptide Immunoaffinity Enrichment Coupled to Multiple Reaction Monitoring Mass Spectrometry for Quantifying Proteins in Plasma* , 2011, Molecular & Cellular Proteomics.
[49] Ying Liang,et al. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. , 2011, Journal of proteome research.
[50] Richard D Smith,et al. Recommendations for Mass Spectrometry Data Quality Metrics for Open Access Data (Corollary to the Amsterdam Principles)* , 2011, Molecular & Cellular Proteomics.
[51] M. Mann,et al. Mass Spectrometry-based Proteomics Using Q Exactive, a High-performance Benchtop Quadrupole Orbitrap Mass Spectrometer* , 2011, Molecular & Cellular Proteomics.
[52] Michel Salzet,et al. Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer , 2011, Analytical and bioanalytical chemistry.
[53] K. Iczkowski,et al. Current Perspectives on Gleason Grading of Prostate Cancer , 2011, Current urology reports.
[54] V. Karantza,et al. Keratins in health and cancer: more than mere epithelial cell markers , 2011, Oncogene.
[55] Zhuchu Chen,et al. Proteomic analysis of the stroma-related proteins in nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissues , 2010, Medical oncology.
[56] Peng Wang,et al. Development of mass spectrometry-based shotgun method for proteome analysis of 500 to 5000 cancer cells. , 2010, Analytical chemistry.
[57] R. Shah,et al. Current perspectives on the Gleason grading of prostate cancer. , 2009, Archives of pathology & laboratory medicine.
[58] Lisa H Cazares,et al. Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue , 2009, Clinical Cancer Research.
[59] M. Mann,et al. In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.
[60] E. Petricoin,et al. Laser Capture Microdissection , 1996, Science.
[61] Beth Katcher,et al. Development of an integrated prostate cancer research information system. , 2006, Clinical genitourinary cancer.
[62] P. Humphrey,et al. Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.
[63] B. Hammock,et al. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[64] M. Mann,et al. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.
[65] Complexity staff. Research article: merging bottom-up and top-down approaches to study prostate cancer biology , 2002 .
[66] W. Demark-Wahnefried,et al. Zinc α-2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer , 2001 .
[67] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.